188 Re-SSS Lipiodol Radioembolization in HCC Patients: Results of a Phase 1 Trial (Lip-Re-01 Study).

Etienne GarinXavier PalardYan RollandSamuel Le SourdNicolas LepareurValérie ArdissonChristelle BouvrySophie LaffontBoris Campillo-GimenezEric BellissantJulien Edeline

Published in: Cancers (2023)

Re-SSS lipiodol was confirmed, resulting in encouraging responses for a Phase 1 study. As the 3.6 GBq activity proved to be safe, it will be used in a future Phase 2 study.

Keyphrases

end stage renal disease
open label
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
peritoneal dialysis
double blind
clinical trial
current status
patient reported
patient reported outcomes
study protocol